Tirzepatid 30 MG

▎ Tsarin Tirzepatid

▎ Binciken Tirzepatid

Menene asalin binciken Tirzepatid?

Asalin bincike na Tirzepatid da farko ya samo asali ne daga binciken magungunan maganin ciwon sukari da kuma buƙatar magungunan sarrafa nauyi. Magungunan maganin ciwon sukari na al'ada suna da iyakancewa, yayin da masu karɓar masu karɓar GLP-1 suna nuna tasiri mai mahimmanci wajen inganta sarrafa glucose na jini, yana sa masu bincike su samar da magunguna masu inganci na aji ɗaya. A matsayin GIP/GLP-1 dual agonist mai karɓa, Tirzepatid zai iya daidaita matakan glucose na jini mafi kyau. Haɓaka yawan kiba da kiba a duniya ya sanya sarrafa nauyi ya zama buƙatar asibiti na gaggawa. GLP-1 agonists mai karɓa yana da tasirin rage nauyi, yana mai da su manufa don asarar nauyi. Tirzepatid ya sami kulawa saboda kyakkyawan sakamako na asarar nauyi.

Menene tsarin aikin Tirzepatid?

Dual receptor agonist aiki: 

Tirzepatid mai dual glucagon-kamar peptide-1 (GLP-1) da insulinotropic polypeptide (GIP) mai dogaro da glucose mai agonist [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 da GIP dukkanin hormones na incretin da aka samar a cikin hanji, suna taka muhimmiyar rawa wajen kiyaye glucose homeostasis. Tirzepatid yana haifar da tasirin daidaitawa ta hanyar kunna GLP-1 da masu karɓar GIP a lokaci guda, don haka daidaita matakan glucose na jini.

Dokokin insulin da kuma fitar da glucagon: 

Yana ƙara haɓakar insulin da ɓoyewa yayin da yake rage sakin glucagon ta hanyar dogaro da glucose. Lokacin da matakan glucose na jini ya tashi, Tirzepatid yana motsa ƙwayoyin β-pancreatic don ɓoye insulin, yana haɓaka haɓakar glucose da amfani, ta haka yana rage matakan glucose na jini; a lokaci guda, yana hana ƙwayoyin α-pancreatic daga ɓoye glucagon, rage yawan fitowar glucose na hanta, ƙara rage matakan glucose na jini, da sarrafa saurin azumi da matakan glucose na jini na gaba ^[1,3]..

Sauran hanyoyin aiki: 

Tirzepatid kuma yana haɓaka satiety, wanda zai iya kasancewa yana da alaƙa da kunna masu karɓar GLP-1, yin aiki akan tsarin juyayi na tsakiya, da kuma tasirin cibiyoyin sarrafa abinci, yana jagorantar marasa lafiya don rage cin abinci kuma ta haka ne ke taimakawa asarar nauyi. Hakanan yana jinkirta zubar da ciki, yana tsawaita lokacin da abinci ya kasance a cikin ciki kuma a hankali yana shiga cikin ƙananan hanji, don haka yana hana haɓakar matakan glucose na jini cikin sauri ^[1].

Hoto 1 Tsarin aikin T irzepatide ^[6].

Menene aikace-aikacen T irzepatide?

Jiyya na nau'in ciwon sukari na 2: 

An yarda da Tirzepatid don kula da tsofaffi marasa lafiya da nau'in ciwon sukari na 2 a matsayin haɗin kai ga abinci da motsa jiki. Gwajin SURPASS ya nuna cewa Tirzepatid yana rage yawan haemoglobin A1c (HbA1c), tare da raguwa daga -1.87% zuwa -2.59% (-20 zuwa -28 mmol/mol). Hakanan yana nuna ingantaccen sarrafa glycemic idan aka kwatanta da wasu agonists masu karɓa na GLP-1, kamar semaglutide 1 MG a cikin gwajin SUPRASS-2. Bugu da ƙari, yana iya rage nauyin jiki, tare da asarar nauyi daga -6.2 zuwa -12.9 kg a cikin nazarin asibiti, wanda ke da mahimmanci ga marasa lafiya da nau'in ciwon sukari na 2 waɗanda galibi suna da matsalolin kiba ko kiba ^[1,4].

Maganin Kiba: 

Tun da Tirzepatid yana haɓaka satiety, yana rage cin abinci, da haɓaka asarar nauyi, yana da yuwuwar ƙimar warkewa ga marasa lafiya da kiba. Nazarin ya nuna cewa yana iya rage nauyi da sama da 20%, inganta yanayin rayuwa na marasa lafiya, kuma ya zama sabon zaɓi na magani don kiba, yana taimaka wa marasa lafiya su rasa nauyi da rage haɗarin cututtukan daban-daban waɗanda ke da alaƙa da kiba ^[1,2].

Rage haɗarin cututtukan zuciya: 

Marasa lafiya da ke da nau'in ciwon sukari na 2 galibi suna fuskantar haɗarin cutar cututtukan zuciya. Baya ga rage sukarin jini da nauyi, Tirzepatid yana da tasiri mai kyau akan alamomin da ke da alaƙa da jijiyoyin jini, gami da rage hawan jini, rage yawan kitse na visceral, da rage yawan matakan triglyceride, don haka yana taimakawa wajen rage haɗarin cututtukan cututtukan zuciya da haɓaka sakamakon bugun jini na marasa lafiya ^[4].

Yiwuwar magani don steatohepatitis mara-giya (NASH): 

Tirzepatid yana da yuwuwar tasirin warkewa akan NASH. Ta hanyar haɓaka hankalin insulin da daidaita glucose da metabolism na lipid, zai iya rage ciwon hanta da kumburi, yana ba da sabon jagora don maganin NASH ^[5].

Kammalawa

A matsayin GIP/GLP-1 dual agonist agonist, Tirzepatid ya nuna tasiri mai mahimmanci a cikin maganin ciwon sukari da rashin lafiya. Ta hanyar daidaita ƙwayar insulin da glucagon, jinkirta zubar da ciki, da haɓaka satiety, yana rage matakan haemoglobin A1c yadda ya kamata kuma yana rage nauyin haƙuri. Bugu da ƙari, miyagun ƙwayoyi yana inganta abubuwan haɗari na zuciya da jijiyoyin jini kamar matakan lipid da hawan jini kuma yana nuna tasiri a cikin steatohepatitis maras barasa.

Game da Marubuci

Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.

Mawallafin Jaridar Kimiyya

De Block C yana da alaƙa da Jami'ar Antwerp da cibiyoyin da ke da alaƙa a Belgium, gami da Inflamed Ctr Excellence, Asibitin Jami'ar Antwerp (UZA da Univ Hosp Antwerp), da Infla Med Ctr Excellence. Bincikensa ya shafi fannoni da yawa, irin su Endocrinology & Metabolism, inda ya mayar da hankali kan kwayoyin halitta da cututtuka na rayuwa; Gastroenterology & Hepatology, bincikar cututtuka na narkewa da hanta; Janar & Magungunan Ciki, magance ganewar asali da kuma kula da cututtuka na ciki; Nutrition & Dietetics, bincikar abinci mai gina jiki da tasirinsa na lafiya; da Urology & Nephrology, nazarin ilimin cututtuka da aikin asibiti na cututtukan urinary da koda. Shi masani ne wanda ke da gagarumar gudunmawa ga fannonin kiwon lafiya da yawa. An jera De Block C a cikin ambaton ambaton [4].

▎ Abubuwan da suka dace

[1] Wong E, Cope R, Dima L, et al. Tirzepatid: A Dual Glucose-dogara Insulinotropic Polypeptide da Glucagon-Kamar Peptide-1 Agonist don Gudanar da Nau'in 2 Ciwon sukari Mellitus[J]. Jaridar Amirka ta Therapeutics, 2023,30 (1): e26-e35.DOI: 10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, et al. Bayani akan Tirzepatid, Jiyya na Dual-Niyya don Ciwon sukari da Kiba[J]. Jarida ta kasa da kasa na Bincike da Ci gaba, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, et al. Tirzepatid wani labari na kwayar cutar ciwon sukari ya bayyana aiki biyu [J]. Gano Kiwon Lafiyar Jama'a, 2024,21(1):75.DOI:10.1186/s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, et al. Tirzepatid don kula da manya da nau'in ciwon sukari na 2: hangen nesa na endocrin [J]. Kiba da Ciwon sukari & Metabolism, 2023,25(1):3-17.DOI:10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, et al. Juya kulawar ciwon sukari: bayyana yuwuwar Tirzepatid a cikin sarrafa glycemic da bayan [J]. Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru, 2024,17 (3): 235-246.DOI: 10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, et al. Daga tsarin glycocentric a cikin mai haƙuri tare da nau'in ciwon sukari na 2 zuwa maganin rigakafin ƙwayoyin cuta da yawa da raguwa a cikin sakamakon neuro-nephro-cardiovascular.[M]//2023.DOI: 10.5772/intechopen.1002363.

DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.  

Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.